NCT00594854View on ClinicalTrials.gov

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

PHASE3TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Gastric Ulcer
Interventions
DRUG

PN400 (VIMOVO)

PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).

DRUG

Diclofenac/Misoprostol

Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.

Trial Locations (1)

27517

POZEN, Chapel Hill

Sponsors

Lead Sponsor

POZEN
All Listed Sponsors
lead

POZEN

INDUSTRY

NCT00594854 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec | Biotech Hunter | Biotech Hunter